Project description DEENESFRITPL Advancing PET measurement of myocardial blood flow The assessment of myocardial blood flow is carried out by positron emission tomography (PET) using 15O-water, a radioactive variation of regular water as a tracer. However, the short half-life of 15O-water alongside difficulties in image analysis have prohibited its widespread clinical use. Scientists of the EU-funded EU-CAD project are working on a new hardware and analytical software combination to aid clinicians all over the world with 15O-water PET images. The project aims to further develop the current prototype and validate it in patients before obtaining regulatory approval to operate in Europe. Given the implication of myocardial blood flow in coronary heart disease, a robust measurement approach will help patient outcomes. Show the project objective Hide the project objective Objective Coronary artery disease (CAD) is a disease blocking blood flow to the heart. Identifying patients with limited blood flow is key in improving patient outcomes. 15O-water is the undisputed gold standard tracer for blood flow assessment, with more than 450 publications on the topic. However, the ultra-short half-life of 15O -water, the difficult image analysis and the lack of regulatory approved equipment have limited its use in clinical practice. This limits the transition from current practice (SPECT, with poor accuracy and low throughput) to PET. With MedTrace’s solution of hardware and analytical software, clinicians all over the world will get routine access to 15O-water PET, achieving unrivalled accuracy at a low-cost while increasing patients’ comfort.MedTrace’s addressable market potential draws on the installed base of current PET scanners (>500,000 worldwide in 2017), tapping into a multi-billion-euro opportunity for every 1% that starts using 15O-water. This market is even larger as we further build the evidence that 15O-water PET scans are safer and more cost-effective than current clinical practice. We are asking for grant funding to further mature our working prototype solution, validate it in a small cohort of patients in three different EU sites, and obtain CE approval to operate in Europe. We also ask for equity funding to scale in the US by conducting a phase III clinical trial for regulatory approval in the US. This will allow us to overcome all the remaining regulatory barriers and improve cardiac imaging worldwide. Fields of science natural sciencescomputer and information sciencessoftware Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2b - SME Instrument (grant only and blended finance) Coordinator MEDTRACE PHARMA A/S Net EU contribution € 2 500 000,00 Address Diplomvej 381 2800 Kongens lyngby Denmark See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Hovedstaden Københavns omegn Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 072 775,00
